Articles

Rapidly evolving mast cell leukaemia three years after an allogeneic stem cell transplant for myelodysplasia: A case report

BJH - volume 14, issue 6, october 2023

M. Beltjens MD, R. Lattenist MD, M. Rousseaux MD, P. Saussoy MD, PhD, X. Poiré MD, PhD, N. Straetmans MD, PhD

SUMMARY

We report a patient developing mast cell leukaemia with subsequent multi-organ failure, three years after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. Mast cell leukaemia is a very rare condition, accounting for <1% of all mastocytosis. In this article, we will discuss the atypical disease progression and treatment response, and diagnostic challenges.

(BELG J HEMATOL 2023;14(6):255–8)

Read more

Highlights in haematopoietic stem cell transplantation

BJH - volume 12, issue 1, february 2021

R. Lattenist MD, X. Poiré MD, PhD

SUMMARY

The ASH 2020 annual meeting provided us with several contributions to the field of haematopoietic stem cell transplantation (HSCT). Post-transplant cyclophosphamide (PTCy) held a prominent place on the stage. This modality of graft-versus-host disease (GvHD) prophylaxis, initially developed in the haplo-identical HSCT setting, showed so much benefit that its use tends to spread throughout other types of donors. PTCy seems to be particularly investigated with the mission of improving outcomes in HSCT from mismatched unrelated donors (MMUD), which is of great interest for patients from underserved ethnicities lacking a matched donor. Management of chronic graft-versus-host disease (cGvHD) also had its share of improvement with the presentation of the results of the REACH3 study, comparing ruxolitinib to best available therapy. Reduced intensity conditioning (RIC) for myeloid malignancies got some attention with a boost to the support of its use for higher-risk myelodysplastic syndrome (MDS). We will also highlight an attempt to improve the efficacy of RIC in high-risk myeloid malignancies by the addition of venetoclax in a phase I study.

(BELG J HEMATOL 2021;12(1):33-7)

Read more

O.6 Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation – a multicenter prospective study

BJH - volume 11, issue Abstract Book BHS, february 2020

S. Servais MD, PhD, prof. F. Baron , C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, PhD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD

Read more

Chimeric antigen receptor T-cells: a new therapeutic option for relapsed/refractory B-cell malignancies and beyond

BJH - volume 10, issue 8, december 2019

T. Feys MBA, MSc, G. Roex , Y. Beguin MD, PhD, T. Kerre MD, PhD, X. Poiré MD, PhD, P. Lewalle MD, PhD, P. Vandenberghe MD, PhD, D. Bron MD, PhD, S. Anguille MD, PhD

Chimeric antigen receptor (CAR) T-cell therapy is a new cancer immunotherapy targeting specific cell surface antigens. This type of adoptive cell immunotherapy has been a breakthrough in the treatment of aggressive B-cell lymphoma and B-cell precursor acute lymphoblastic leukaemia (ALL) and is currently also being studied in other cancer types, including multiple myeloma and chronic lymphocytic leukaemia. This review will discuss the recent clinical developments and future perspectives of CAR T-cell therapy, with a focus on the clinical trials that led to the FDA and EMA approval of tisagenlecleucel (Kymriah®, Novartis) and axicabtagene ciloleucel (Yescarta®, Gilead) for the treatment of childhood/adult relapsed/refractory (r/r) B-cell precursor ALL and aggressive B-cell non-Hodgkin lymphoma.

(BELG J HEMATOL 2019;10(8):301–10)

Read more

O6 Analysis of the impact of mismatches at HLA loci DRB3/4/5 on outcomes after allogeneic stem cell transplantation

BJH - 2018, issue Abstract Book BHS, february 2018

F. Van Obbergh MD, N. Vanlangendonck , A. Van Maanen , P. Van Muylder , A. Ferrant , C. Lambert MD, PhD, E. Van den Neste MD, PhD, D. Latinne , X. Poiré MD, PhD

Read more

P61 Drug induced neutropenia with myelodysplasia with blast excess

BJH - 2018, issue Abstract Book BHS, february 2018

A. Capes , F. Dall’Armellina , Y. Berners , L. Maindiaux , T. Connerotte MD, A. Camboni MD, PhD, P. Saussoy MD, PhD, J-P. Defour PhD, X. Poiré MD, PhD, N. Straetmans MD, PhD, M.C. Vekemans MD

Read more

PP06 Hereditary predisposition syndromes to malignant hemopathies (HPSMH)

BJH - 2018, issue Abstract Book BHS, february 2018

S. Dupriez , A. Ferrant , M.C. Vekemans MD, B. Brichard MD, PhD, L. Michaux MD, PhD, T. Connerotte MD, E. Van den Neste MD, PhD, C. Vermylen , L. Knoops MD, PhD, C. Graux MD, PhD, F. Duhoux MD, PhD, C. Lambert MD, PhD, X. Poiré MD, PhD, H.A. Poirel MD, PhD

Read more